{
  "ticker": "IRX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971458",
  "id": "02971458",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250722",
  "time": "1136",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250722/pdf/06m0t8rbljskh5.pdf",
  "summary": "### **InhaleRx Limited (ASX: IRX) \u2013 Quarterly Report (June 2025) Summary**  \n\n**Operational & Financial Highlights:**  \n- **IRX-211 (Breakthrough Cancer Pain):**  \n  - HREC approval secured for Phase 2 trial with minimal queries.  \n  - Trial drug manufacturing commenced; first patient dosing (FPI) expected Q3 2025.  \n  - Additional clinical sites being evaluated to accelerate recruitment.  \n\n- **IRX-616a (Panic Disorder):**  \n  - Phase 1 trial prep underway; HREC submission imminent (FPI targeted Q4 2025).  \n  - GMP manufacturing specifications finalized; site activation in progress.  \n\n- **Funding & Capital:**  \n  - **Clendon funding facility:** First drawdown of **$248k** (total facility: **$38.5m**), covering trial drug manufacturing.  \n  - **R&D rebates:** Received **$402k** (2024) + **$93k** (2023 amendment, incl. interest).  \n\n- **Cash Position:**  \n  - **Net operating inflow: $170k** (boosted by R&D rebates).  \n  - Quarterly expenses: **$196k** (clinical), **$107k** (corporate), **$20k** (directors), **$10k** (salaries).  \n\n**Next Catalysts:**  \n- IRX-211: Site activation, trial drug delivery, and patient dosing (Q3 2025).  \n- IRX-616a: HREC submission and manufacturing commencement.  \n\n*(No capital raising, material M&A, or trading halt information disclosed.)*",
  "usage": {
    "prompt_tokens": 2397,
    "completion_tokens": 357,
    "total_tokens": 2754,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T01:45:06.953161"
}